Gwenn Hansen - 27 Oct 2021 Form 4 Insider Report for Nurix Therapeutics, Inc. (NRIX)

Role: Chief Scientific Officer
Signature: /s/ Christine Ring, as Attorney-in-Fact for Gwenn Hansen
Issuer symbol: NRIX
Transactions as of: 27 Oct 2021
Net transactions value: -$11,096
Form type: 4
Filing time: 28 Oct 2021, 19:23:54 UTC
Previous filing: 04 Oct 2021
Next filing: 02 Nov 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NRIX	Common Stock	Options Exercise	$2,904	+400	+2.8%	$7.26	14,597	27 Oct 2021	Direct	F1
transaction	NRIX	Common Stock	Sale	$14,000	-400	-2.7%	$35.00	14,197	27 Oct 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NRIX	Employee Stock Option (right to buy)	Options Exercise	$0	-400	-0.58%	$0.000000	68,666	27 Oct 2021	Common Stock	400	$7.26	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
F2	The stock option vests as to 1/48 of the total shares monthly beginning February 18, 2020 until the option is fully vested on January 18, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.